CMRA (Comera Life Sciences Holdings) Total Liabilities: $7.29 Mil (As of Sep. 2023)


What is Comera Life Sciences Holdings Total Liabilities?

Comera Life Sciences Holdings CMRA Total Liabilities is $7.29 Mil as of Sep. 2023.

Comera Life Sciences Holdings's Total Liabilities for the quarter that ended in Sep. 2023 was $7.29 Mil.

Comera Life Sciences Holdings's quarterly Total Liabilities increased from Mar. 2023 ($8.26 Mil) to Jun. 2023 ($8.69 Mil) but then declined from Jun. 2023 ($8.69 Mil) to Sep. 2023 ($7.29 Mil).

Comera Life Sciences Holdings's annual Total Liabilities increased from Dec. 2020 ($0.39 Mil) to Dec. 2021 ($22.10 Mil) but then declined from Dec. 2021 ($22.10 Mil) to Dec. 2022 ($9.97 Mil).

Comera Life Sciences Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings Total Liabilities Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Total Liabilities
0.39 22.10 9.97

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 8.37 9.97 8.26 8.69 7.29

Comera Life Sciences Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Comera Life Sciences Holdings's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.059+(0.12+4.795
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.97

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=3.727--6.247
=9.97

Comera Life Sciences Holdings's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.932+(0+4.361
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.29

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=3.072--4.221
=7.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $7.29 Mil mean?
Comera Life Sciences Holdings (CMRA) has a Total Liabilities of $7.29 Mil as of Sep. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' Total Liabilities too high?
Comera Life Sciences Holdings' current Total Liabilities is $7.29 Mil.
How does Comera Life Sciences Holdings' Total Liabilities compare to FREQ and BNTC?
Comera Life Sciences Holdings' Total Liabilities of $7.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current Total Liabilities is $7.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current Total Liabilities of $7.29 Mil. The current Total Liabilities is $7.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current Total Liabilities is $7.29 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.